Compare BDSX & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDSX | BDTX |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.3M | 171.9M |
| IPO Year | 2020 | 2020 |
| Metric | BDSX | BDTX |
|---|---|---|
| Price | $24.00 | $2.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $32.50 | $9.67 |
| AVG Volume (30 Days) | 66.3K | ★ 642.5K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $88,499,000.00 | N/A |
| Revenue This Year | $25.26 | N/A |
| Revenue Next Year | $19.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.08 | N/A |
| 52 Week Low | $0.35 | $1.60 |
| 52 Week High | $25.52 | $4.94 |
| Indicator | BDSX | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.37 | 59.22 |
| Support Level | $19.26 | $1.96 |
| Resistance Level | $24.47 | $2.26 |
| Average True Range (ATR) | 1.73 | 0.10 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 70.61 | 77.88 |
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.